John McKenna

🌟 Partnering with industry experts Oliver Belin and Ziv Shilon to delve into cash optimization and working capital management strategies. As interest rates surge and capital availability fluctuates, the importance of this pivotal and challenging topic has skyrocketed on the CFO’s agenda. If you are a Finance, Procurement or Supply Chain leader - Don’t miss the opportunity to gain insights, hear award-winning journeys, and stay updated on trends in this dynamic field with us this May! Register here! https://lnkd.in/eAC3qQ8Z #webinar #cashflowmanagement #sharingknowledge

58

2 Comments

Great article describing what is necessary to make in-roads for value-based care. It is not just about one engagement, or one aspect of the costs incurred in treating a disease. This explores how all stakeholders (Payers, Providers and Pharmacists) have to be vested in the concept of value for the patient throughout their journey! #VBC #specialtypharmacy #asembia #revhealth

19

1 Comment

As I prepare to join you all tomorrow at the National Pharmaceutical Congress Institute webinar on Pharmacare featuring experts Mihai (Mike) Csaki, Zal Press, Pamela Fralick, and Eileen McMahon, I wanted to share my thoughts. I picked up 3 key pieces of information to put context, perspectives and opinions on this highly-debated reform. 1. Making contraception and diabetes medications free for Canadians The office of Prime Minister issued a communiqué on May 24. Extracts: ·      The medications many Canadians need are often too expensive, leading to fewer visits to pharmacies, less treatment, and more frequent health scares. ·      The cost of contraceptives, and medications for those who are diabetic, is one of the largest barriers to access. ·      We're making sure Canadians get the medication that they need, when they need it. Source: https://rb.gy/q9hdml 2. Improving Coverage and Access to Innovative Medicines for Canadians: Standing Committee of Health study of Bill C-64 On May 22, Innovative Medicines Canada - Médicaments novateurs Canada issued a position statement including context, four recommendations and proposed next steps for a collaborative approach. Extracts: Reco #1: The Government of Canada should build on Canada’s extensive existing coverage rather than replacing it with limited public formularies. The limited available funding should be used to address the unique gaps or limitations in coverage in consultation with each jurisdiction. Reco #2: The Government of Canada should leverage existing efforts to reduce costs currently being undertaken by the pan-Canadian Pharmaceutical Alliance (pCPA) through joint pricing negotiations. Standalone federal initiatives would have limited additional benefit. Source: https://rb.gy/ihldbw 3. Addressing the impact of Bill-64: Healthcare experts weigh in on the pros and cons of the new legislation This week, the National Pharmaceutical Congress Institute issued a white paper including survey results and opinions from industry experts. Extracts: ·      “With the advent of AI and technology, we are living in dynamic times when it comes to healthcare...We have to be supportive of any initiative that wants our best interests, even if it’s not perfect and we struggle to please everybody. There’s no perfect system for everyone. The goal is to aim for the best and try to improve”. ·      The majority (over 50%) of surveyed participants also believed the greatest challenge in implementing Bill C-64 could be the lack of provincial cooperation. Source: https://lnkd.in/gVdiyGUS I look forward to participating in the event and hearing from the panel as we continue to see the shaping of Canadian healthcare changes. My name is Arnaud Lavenue and I'm a senior partner at Toc Toc Communications. I'm passionate about bringing pharmaceutical brands to life to their full potential so that they can help the patients who need them most. Thank you for liking, commenting, or following.

62

4 Comments

Because the health of our planet matters

3

In a new report focusing on portfolio strategy and business development, my colleagues Cody Powers and Josh Hattem share data around #pharma launches and approvals, what’s driving industry growth, why clinical trials continue to decline and more.  https://lnkd.in/edghcwTS

21

🌟 Key Insights from Deloitte’s 2024 Midyear Global Outlook for Life Sciences 🌟 Deloitte's latest report identifies three major disruptors shaping the life sciences sector: 1. Generative AI: Transforming end-to-end processes, with potential to significantly enhance efficiency and cost savings. 2. GLP-1s: Game-changing drugs for obesity management, poised to impact healthcare costs and accessibility. 3. Global Pricing Pressures: Regulations like the US Inflation Reduction Act (IRA) are influencing drug pricing, affecting margins and innovation investment.

2

Check out our #omnichannel webinar this Thursday to get the blueprint that will help you achieve launch success.

10

Great discussion on The Evolving Role of the CFO at Fortune’s Future of Finance conference with Yanela Frias and Xihao Hu. The CFO landscape is rapidly changing, but three key themes emerged: 1. Innovation Ally. Finance must champion innovation, providing a framework for good ideas to succeed because when innovation thrives the bottom line thrives. 2. Strategist, Not Just Steward. Modern “CFO’ing” extends beyond financial stewardship. It requires translating financial goals into actionable strategies for growth. 3. Customer Obsessed. Solving our customer’s problems is key. It requires active listening, anticipating their needs, and relentlessly exceeding expectations. Thanks to Fortune and my fellow panelists for having me. What are your thoughts on the modern CFO?   You can watch here: https://lnkd.in/enXbg7Ei #FortuneFinance #ZoetisProud

214

3 Comments

Explore how VUCA (Volatile, Uncertain, Complex, Ambiguous) can enhance self-improvement. Using the Yerkes-Dodson Law, discover strategies to turn stress into growth and drive peak performance in challenging times.

7

While every company’s situation is unique, in our work with clients, we’ve discovered some key steps for succession planning success. Read insights for each of the steps below: https://lnkd.in/eM4Aujkf 1. Plan ahead 2. Consider the company strategy 3. Develop a capabilities profile 4. Identify and assess candidates 5. Manage the transition #SuccessionPlanning #ChangeManagement #OrgCulture #StrategicPlanning

1

CIOs and IT leaders routinely make a “business case” to secure funding for technology initiatives. Yet, many provider technology projects lose their stakeholder value during execution. Learn how to form powerful partnerships with your C-suite peers in Gartner's complimentary webinar. #Technology #CIO #Leadership #Webinar

5

Communications can be an organization’s superpower. In this article, my colleagues Dana Maor, David Honigmann, James Naylor and Eric Sherman share five ways leaders can inspire, engage, and unlock the full potential of their teams. #leadership #communication

2

The specialty therapeutics access landscape is changing quickly. In a recent article, I explore implications of specialty carveouts & copay accumulators / maximizers on patient access & manufacturer patient support programs and highlight opportunities for pharma companies to respond. Check out the full article below. https://lnkd.in/gx_Hcn_T

47

2 Comments

The 340B Drug Pricing Program has grown significantly in recent years. States have responded by passing additional legislation, creating a complex policy landscape that’s challenging for both manufacturers and providers. My colleagues explore pharma’s and states’ policy responses, analyze how successful these responses have been and offer recommendations for how pharma can adapt in a dynamic environment.  #healthcare #pharma #340B #drugpricing #publicpolicy https://lnkd.in/eJwm-NrN

8

The biopharma industry is rebounding in 2024. Investments in cutting-edge technologies like antibody drug conjugates and AI, along with strategic alliances, are shaping the future of medicine. Henry Levy discusses how the sector is poised for transformative advancements in healthcare. https://ow.ly/mltI30sE6nV #Biopharma #PharmaInvestments #FutureOfMedicine #Healthcare #Biotech

6

Check out my BCG colleagues recent report that focuses on improving #healthequity with patient analytics. The research unveils significant disparities in the treatment of Heart Failure with Reduced Ejection Fraction (HFrEF) across the United States. Focusing on areas with notably low engagement, particularly in under-served urban areas. Explore the findings and actionable strategies here: https://lnkd.in/gbMpC9d8

9